TSC22D1 Antibody | CSB-PA993921

(No reviews yet) Write a Review
SKU:
CSB-PA993921
Availability:
3 to 7 Working Days
  • TSC22D1 Antibody
  • The image on the left is immunohistochemistry of paraffin-embedded Human prostate cancer tissue using CSB-PA993921 (TSC22D1 Antibody) at dilution 1/30, on the right is treated with fusion protein. (Original magnification: ×200)
€315.80 - €488.70

Description

TSC22D1 Antibody | CSB-PA993921 | Cusabio

TSC22D1 Antibody is Available at Gentaur Genprice with the fastest delivery.

Online Order Payment is possible or send quotation to info@gentaur.com.

Product Type: Polyclonal Antibody

Target Names: TSC22D1

Aliases: TSC22 domain family, member 1

Background: This gene encodes a member of the TSC22 domain family of leucine zipper transcription factors. The encoded protein is stimulated by transforming growth factor beta, and regulates the transcription of multiple genes including C-type natriuretic peptide. The encoded protein may play a critical role in tumor suppression through the induction of cancer cell apoptosis, and a single nucleotide polymorphism in the promoter of this gene has been associated with diabetic nephropathy. Alternatively spliced transcript variants encoding multiple isoforms have been observed for this gene.

Isotype: IgG

Conjugate: Non-conjugated

Clonality: Polyclonal

Uniport ID: Q15714

Host Species: Rabbit

Species Reactivity: Human, Rat

Immunogen: Full length fusion protein

Immunogen Species: Human

Applications: ELISA, IHC

Tested Applications: ELISA, IHC;ELISA:1:2000-1:5000, IHC:1:25-1:100

Purification Method: Antigen affinity purification

Dilution Ratio1: ELISA:1:2000-1:5000

Dilution Ratio2: IHC:1:25-1:100

Dilution Ratio3:

Dilution Ratio4:

Dilution Ratio5:

Dilution Ratio6:

Buffer: -20°C, pH7.4 PBS, 0.05% NaN3, 40% Glycerol

Form: Liquid

Storage: Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.

Initial Research Areas: Epigenetics and Nuclear Signaling

Research Areas: Epigenetics & Nuclear Signaling

View AllClose

0 Reviews

View AllClose